AF
VKTX icon

Amalgamated Financial’s Viking Therapeutics VKTX Stock Holding History

Amalgamated Financial’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$25K Buy
+8,272
New +$29.7K ﹤0.01% 2679

Other funds holding VKTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Amalgamated Financial's VKTX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Viking Therapeutics (VKTX) in Q1 2022: 8,272 shares worth $25K. The stake represents ﹤0.01% of the portfolio and ranks #2679 among its holdings.

140 funds tracked by Wall St. Rank hold VKTX as of Q1 2022.

  • Amalgamated Financial held 8,272 shares of Viking Therapeutics worth $25K as of Q1 2022.
  • Viking Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Viking Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2679 holding.
  • 140 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.